GlassScriptPhysician profile
Sana Hanif
NPI 1841607397
$2,897.39
in general payments reported to CMS, 2019-2025
22 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.89 · 2021: $502 · 2022: $714 · 2023: $693 · 2024: $584 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $779.53 | 2021-2025 | |
| Pfizer INC. | $487.27 | 2019-2025 | |
| Heartflow, INC. | $252.64 | 2022-2024 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $232.27 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $159.12 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $137.26 | 2021-2023 | Verquvo |
| Baxter Healthcare | $116.46 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $102.69 | 2021-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $84.69 | 2022-2024 | Farxiga |
| Astellas Pharma US INC | $75.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.08 | 2023-2024 | Jardiance |
| Biotronik INC. | $66.69 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.48 | 2024-2025 | Lifevest |
| Amgen INC. | $53.73 | 2021-2023 | Repatha |
| Boston Scientific Corporation | $43.51 | 2023-2024 | Watchman Flx, Watchman Access System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $32.01 | 2021 | |
| Irhythm Technologies, INC. | $30.33 | 2021-2022 | |
| Haemonetics Corporation | $25.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.12 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.80 | 2022 | |
| Cvrx, INC. | $20.69 | 2022 | |
| Bardy Diagnostics, INC. | $19.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Hanif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.